Evidence mapPaperPMID 40173289Full record

Observational studyDiabetic medicine : a journal of the British Diabetic Association2025

Optimisation of care among patients with diabetes mellitus and acute coronary syndrome through a specialised cardiodiabetes service-A registry study.

Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee

Abstract readObservational Study
In one paragraph

Observational study in Diabetic medicine : a journal of the British Diabetic Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Usman ShahCardiorenal Group, Diabetes, Metabolism, & Inflammation, Joseph Bank Laboratories, University of Lincoln, Lincoln, UK.ORCID https://orcid.org/0000-0002-5034-064X
Alun RoebuckLincoln Heart Centre, United Lincolnshire Hospitals, Lincoln, UK.
Bala SrinivasanDepartment of Diabetes and Endocrinology, United Lincolnshire Hospitals, Lincoln, UK.
Paul Edward SquiresCardiorenal Group, Diabetes, Metabolism, & Inflammation, Joseph Bank Laboratories, University of Lincoln, Lincoln, UK.
Claire Elizabeth HillsCardiorenal Group, Diabetes, Metabolism, & Inflammation, Joseph Bank Laboratories, University of Lincoln, Lincoln, UK.
Maxime InghelsLincoln Institute for Rural and Coastal Health, University of Lincoln, Lincoln, UK.
Kelvin LeeCardiorenal Group, Diabetes, Metabolism, & Inflammation, Joseph Bank Laboratories, University of Lincoln, Lincoln, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDiabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose-lowering therapies with cardiovascular benefit in optimising the cardiometabolic profile of patients with type 2 diabetes mellitus. However, uptake remains low. This study was carried out to assess the impact of a novel cardiodiabetes service for the management of patients with diabetes mellitus presenting with acute coronary syndromes.

methodsA retrospective, observational, registry-based analysis was performed among patients presenting with an acute coronary syndrome and diabetes mellitus to a regional heart centre before and after the implementation of a cardiodiabetes service. Intergroup comparison was made for the proportion of patients having a valid glycated haemoglobin during admission, initiation of guideline-recommended glucose and lipid-lowering therapies.

resultsAt median follow-up of 29.7 months, a valid HbA1c measurement at baseline was lower in the pre-intervention compared to the post-intervention group (556/711 [78.2%] vs. 302/362 [83.4%], p = 0.043) while more patients in the post-intervention group were prescribed sodium-glucose co-transporter inhibitors (297/362 [82.0%] vs. 359/711 [50.5%]). All-cause mortality (5.2 vs. 12.3 [events/100 patient-years], relative ratio [RR] 0.42, 95% confidence interval [CI] 0.28-0.61, and p < 0.001), first events of acute kidney injury (AKI) (10.0 vs. 13.0, RR 0.77, CI 0.57-1.03, p = 0.090) and all events of AKI (16.6 vs. 22.1, RR 0.75, CI 0.60-0.94, p = 0.015) were significantly lower in the post-intervention group.

conclusionThe introduction of a joint-speciality cardiodiabetes service improved the care and survival of patients with acute coronary syndrome and diabetes mellitus.

Indexed as

Acute Coronary SyndromeDiabetes Mellitus, Type 2Diabetic AngiopathiesHypoglycemic AgentsAgedBlood GlucoseFemaleGlycated HemoglobinHumansMaleMiddle AgedRegistriesRetrospective StudiesBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsacute coronary syndromecardiovascular outcomesdiabetes mellitustreatment optimisation

Identifiers

PMID40173289
PMCPMC12080982

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.